Abstract
Methods In Phase I/II clinical trials, 12 subjects with confirmed mutations in the RPE65 gene causing inherited retinal degeneration were given a unilateral sub-retinal injection of AAV.RPE65 into the worse seeing-eye. Objective and subjective visual testing were performed at baseline and following intervention. Subsequently, 11/12 subjects received injections in the contralateral eye, in a Phase II follow on study. These results have initiated the first Phase III clinical trial for retinal disease. The methods and technology used in this study have enabled gene transfer to cells involved with ciliopathies. Unilateral subretinal, intraotocyst, and retrograde ureteral injections of AAV vectors were carried out in cohorts of mice. Intra-otocyst injections were carried out at embryonic day 12; ocular and renal injections were performed in adult mice. The transgene cassette consisted of a CMV-promoted EGFP and/or a luciferase transgene. Transgene expression was evaluated qualitatively and quantitatively over time. Cellular specificity of expression was evaluated histologically. Delivery of the vector was well tolerated locally and systemically and the animals showed no alteration in behavior or general well-being.
Highlights
To report the current state of adeno-associated virus mediated retinal gene therapy for inherited retinal degenerations caused by the RPE65 gene, and its application to auditory, renal and ocular ciliopathies
The methods and technology used in this study have enabled gene transfer to cells involved with ciliopathies
In respect to the animal studies for ciliopathies, the cellular specificity and efficiency of transduction differed for each vector/delivery approach
Summary
Gene therapy clinical trials for childhood blindness and its applications for ocular, auditory and renal ciliopathies. From Cilia 2014 - Second International Conference Paris, France. Purpose To report the current state of adeno-associated virus mediated retinal gene therapy for inherited retinal degenerations caused by the RPE65 gene, and its application to auditory, renal and ocular ciliopathies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.